Clinical Trials Logo

Lung Diseases clinical trials

View clinical trials related to Lung Diseases.

Filter by:

NCT ID: NCT00512967 Completed - COPD Clinical Trials

The Occurence of Inflammation and Oxidative Stress in Lung Diseases

Start date: September 2005
Phase: N/A
Study type: Observational

Reactive oxygen species (ROS) are suggested to play a pivotal role in ILD. Little is known, however, about the endogenous antioxidant levels in ILD that can offer protection against ROS. It is expected that the high amount of ROS present in ILD will reduce the antioxidant levels. Therefore, antioxidant therapy to strengthen this reduced antioxidant defense might be efficacious in ILD treatment. Since ROS are capable of initiating and mediating inflammation, antioxidant therapy might also mitigate elevated inflammation. A candidate for antioxidant therapy is the flavonoid quercetin that is known for its anti-oxidative and anti-inflammatory capacities. The aim of the present study is to determine the antioxidant and inflammatory status in ILD, i.e. sarcoidosis and idiopathic pulmonary fibrosis (IPF). Furthermore, to evaluate the possible anti-inflammatory effects of antioxidants, the effect of quercetin will be examined on the ex vivo LPS-induced cytokine production in ILD

NCT ID: NCT00511290 Completed - Asthma Clinical Trials

Measurement of Soluble Factors and Particulate Matter in Induced Sputum and EBC in Inflammatory Diseases of the Lung

Start date: n/a
Phase: N/A
Study type: Observational

In the present study inflammatory mediators will be isolated in induced sputum and exhaled breath condensate and will be correlated with particulate matter measured in these samples.Particulate matter will be assessed by partcle size distribution method and shape analysis. The aim of the study is to perform biological monitoring in environmental and occupational diseases in a non invassive fashion.

NCT ID: NCT00510510 Completed - Clinical trials for Chronic Obstructive Pulmonary Disease (COPD)

Safety and Tolerability of 28 Days Treatment With Glycopyrronium Bromide (NVA237) (100 or 200 µg Once a Day) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

Start date: August 2007
Phase: Phase 2
Study type: Interventional

This study assessed the safety/tolerability of 28 days of treatment with NVA237 100 µg and 200 µg once a day, compared to placebo in patients with moderate or severe Chronic Obstructive Pulmonary Disease (COPD).

NCT ID: NCT00507949 Completed - Clinical trials for Chronic Obstructive Pulmonary Disease

Study to Evaluate the Effect of Megestrol Acetate in Severe Chronic Obstructive Pulmonary Disease With Loss of Weight

Start date: October 2006
Phase: Phase 2
Study type: Interventional

The purpose of this trial is to study the effect of megestrol acetate in the gain of body weight in patients with severe Chronic obstructive pulmonary disease in order to improve the survival of the patients.

NCT ID: NCT00507234 Completed - Clinical trials for Chronic Obstructive Pulmonary Disease

Study in Subjects Greater Than 40 Years of Age With COPD

Start date: March 2007
Phase: Phase 3
Study type: Interventional

This is a multicenter, Phase IIIb, randomized, double-blind, active-controlled, parallel-group, comparative study. The objectives of this study are: 1. To compare the efficacy of tiotropium 18 mcg once daily plus Formoterol Fumarate Inhalation Solution (FFIS) 20 mcg twice daily to tiotropium 18 mcg once daily. 2. To obtain safety data on the use of tiotropium 18 mcg once daily plus FFIS 20 mcg twice daily compared to tiotropium 18 mcg once daily.

NCT ID: NCT00504738 Completed - Asthma Clinical Trials

Lung Disease Collection (Qatar): Evaluation of the Lungs of Individuals With Lung Disease

Q-LD
Start date: April 2006
Phase: N/A
Study type: Observational

The purpose of this protocol is to obtain biologic samples from the blood and lungs from patients with lung diseases in order to study the causes and indications of these disorders, learn how these lung disease manifest and progress, and how the lung disease can be treated.

NCT ID: NCT00504439 Completed - Clinical trials for Pulmonary Disease, Chronic Obstructive

A Study To Evaluate The Safety And Tolerability Of SB-656933-AAA Following Repeated Doses In Healthy Adult Subjects

Start date: June 4, 2007
Phase: Phase 1
Study type: Interventional

To assess safety of SB-656933 following repeat dosing for 14 days.

NCT ID: NCT00504361 Completed - Asthma Clinical Trials

Blood Collection From Individuals With Lung Disease for Genetic Studies (Qatar)

Q-BC
Start date: May 2006
Phase: N/A
Study type: Observational

This is a research study where researchers are collecting blood to evaluate the genetic characteristics of individuals with chronic lung diseases, including asthma, COPD (chronic obstructive pulmonary disease), interstitial lung disease, cystic fibrosis, and lung cancer. The investigators hope to be able to identify an association between a genetic make-up in the blood samples and the risks of developing a particular lung disease, or severity of a lung disease. The findings of this study might be important to develop future preventative methods and potential treatments for the management of lung disease.

NCT ID: NCT00501852 Completed - Clinical trials for Chronic Obstructive Pulmonary Disease

Efficacy and Safety of Four Doses of Glycopyrronium Bromide (NVA237) in Patients With Stable Chronic Obstructive Pulmonary Disease (COPD), in Comparison to an Active Comparator Tiotropium

Start date: July 2007
Phase: Phase 2
Study type: Interventional

This study will assess the efficacy and safety of glycopyrronium bromide (NVA237) in patients with stable COPD, in comparison to an active comparator.

NCT ID: NCT00500864 Completed - Clinical trials for Chronic Obstructive Pulmonary Disease (COPD)

Magnesium Loading in Chronic Obstructive Pulmonary Disease

Start date: August 2004
Phase: Phase 1/Phase 2
Study type: Interventional

Dietary magnesium (Mg) intake has been shown to be independently related to lung function, airway reactivity, and respiratory symptoms in the general population. Inhaled Mg and IV Mg administration have been shown to promote bronchodilation and to improve lung function in asthmatic patients. Some studies have suggested that COPD patients exhibit decreased body levels of Mg. The purpose of the present study was to investigate the effects of acute IV Mg loading on parameters of respiratory function and maximal exercise capacity of stable COPD patients.The study hypothesis is that Mg administration will be associated to improvements on airflow and vasodilation leading to improvements of pulmonary function and exercise performance.